New Delhi: Even as global economic uncertainty drags down trade, Indian pharmaceutical exporters are seeing growth in Brazil and Nigeria as both countries are emerging as important overseas markets. Data by the commerce ministry data shows that Nigeria has been a major driver of this shift. During the first eight months of the current financial year, exports to the West African nation rose by $179 million, making it one of the fastest growing destinations for Indian drug shipments. This increase alone accounted for more than 14% of India’s total export growth in the
Brazil has also gained prominence in India’s export map. Data for April to November FY26 shows that shipments to the South American country climbed by close to $100 million, underlining its rising importance for Indian pharmaceutical companies.
An official linked this trend to structural changes in these markets, saying, “These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India’s role as a preferred supplier to high growth demand intensive regions.”
Overall, India’s pharmaceutical exports continued to expand, rising 6.5% to $20.48 billion during April-November 2025-26.
However, even as new markets are growing, the United States remains India’s largest export destination, accounting for more than 31% of total pharma exports. At the same time, growing demand across regions is improving the resilience of India’s export profile. According to the official, this broader geographic base is strengthening the stability of the country’s pharmaceutical export basket.
Several other countries also posted steady growth. France, the Netherlands, Canada, Germany and South Africa all recorded increases in imports of Indian pharmaceuticals, jointly supporting overall export expansion while maintaining stable shares.
The Netherlands, in particular, added over $58 million in exports, pointing to India’s growing integration with European pharmaceutical distribution systems.
The commerce ministry official said, “This combination of scale markets and diversified secondary destinations highlights a balanced export architecture, where growth is supported by both mature healthcare systems and fast expanding emerging economies.”
